Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
InChi: InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20
Smiles: COC1=CC2=NC=NC(NC3=CC(Cl)=C(F)C=C3)=C2C=C1O
Objective responses were not observed for the solid tumor or ALL xenografts
(+)-Apogossypol is expected to exhibit lower toxicity while maintaining the significant anti-growth and anti-tumor activities in vitro
Prasugrel - CAS# 150322-43-3 lupirtine Maleate InChi: InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20Prasugrel (marketing name Effient in the US, Efient in the EU and Prasita in India) is a novel platelet inhibitor developed by Daiichi Sankyo Co. and produced by Ube and currently marketed in the United States in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). Prasugrel was approved for use in Europe in February 2009, and is currently available in the UK. On July 10, 2009, the
US$ 195.00
US$ 207.56
US$ 916.85
US$ 189.00
US$ 158.48
US$ 103.60
US$ 428.38
US$ 236.91